Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (31549)	3/29/2005 4:26:47 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 32384

FWIW - I joined the LGND longs this afternoon. ij

To: fred hayes who wrote (31549)	3/29/2005 5:12:26 PM
From: nigel bates	Read Replies (2) \| Respond to of 32384

The recent RP deal related only to three Pfizer and Wyeth compounds, from the 10Q - In November 2004, Ligand and Royalty Pharma agreed to amend their existing royalty agreement for three selective estrogen receptor modulator (SERM) products now in late-stage development with two of the Company's collaborative partners, Pfizer and Wyeth. Under the revised agreement, Royalty Pharma agreed to purchase an additional 1.625% royalty on future sales of the SERM products for $32.5 million. Payments from the royalty purchase are non-refundable and Royalty Pharma has no remaining royalty purchase options. Ligand expects to recognize the $32.5 million as other revenue upon receipt in the fourth quarter of 2004... Doesn't include the Glaxo thrombopoetin mimic - Message 21026605 The Lilly compound - ...A few notes from 2/23 BioCEO Conference - 8 compounds in phase II, with expectation that two are moving this year to phase III (LY818 Type II Diabetes,SB497115 (GSK) Thrombocytopenia)... or the TAP collaboration (if anyone knows what that is ??).